Healis Therapeutics Announces Supply Agreement With CKD Bio to Develop CKDB-501 for Neuropsychiatric Indications
Healis Therapeutics recently announced it has entered into a supply agreement with CKD Bio Corporation (A063160.KS) for CKDB-501, a neuromodulator BoNT/A protein. CKD Bio is a subsidiary of Chong Kun Dang group based in Seoul, South Korea.
Healis Therapeutics intends to develop CKDB-501 for Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD). Healis plans to enter clinical trials in the US and other countries. “We are excited to work with CKD Bio, a global leader in biologics, on a collaboration to develop CKDB-501 for MDD and PTSD” said Dr. Eric Finzi, Co-Founder of Healis, who started the field of BoNT/A for depression research.
Worldwide, approximately 280 million patients experience Major Depressive Disorder (MDD) annually, according to the World Health Organization (WHO). In the US alone, 22 million patients suffer from MDD and 20 million from PTSD, annually, according to data collected by the National Institutes of Mental Health and Department of Veterans Affairs.
“Our collaboration with CKD Bio on this new agreement could one day impact over 42 million Americans,” said Sebastian De Beurs, Co-Founder of Healis. “This planned clinical development represents the largest patient population and market opportunity of any therapeutic indication in the history of BoNT/A.”
Ten randomized controlled trials conducted in 5 countries to date have shown promising early results on glabellar Botulinum Toxin Type A (BoNT/A) treatments for Major Depressive Disorder (MDD). “We hope this partnership will accelerate the development of BoNT/A as a potential on-label treatment available to millions of MDD and PTSD patients worldwide” said Dr. Finzi.
CKDB-501 is a neuromodulator Serotype A botulinum toxin (BoNT/A) protein in development by CKD Bio Corp. CKD Bio Corp is listed on the Korea Stock Exchange (A063160.KS). Healis Therapeutics is a neurotherapeutics company advancing the treatment of neuropsychiatric and neurodegenerative disease. For more information, visit www.healisthera.com.
Total Page Views: 724
